Acepodia was founded in 2017 by Dr. Patrick Y. Yang, former EVP of Juno Therapeutics, Roche, and Genentech, and by Dr. Sonny Hsiao, UC Berkeley Cell Biologist and one of the inventors of Acepodia’s core technology, which is derived from the research on click chemistry and bioorthogonal chemistry by the 2022 Nobel Prize winner in Chemistry, Professor Carolyn Bertozzi of Stanford University. Dr. Hsiao is also one of the co-inventors of this technology. Acepodia is a pubilc biotechnology company focused on developing novel, targeted, allogeneic cell therapies to treat cancers. Acepodia is employing a flexible therapeutic design that leverages cutting-edge technologies to develop the next generation of off-the-shelf cell therapies by supercharging select oNK cells and gamma delta (γδ) T cells to target and engage cancer cells. Our approach is based on developing the most potent immune cells possible and equipping them with the optimal cellular targeting mechanisms needed to engage cancer cells with proprietary platform technologies. By arming our powerful cancer-killing cells with our tumor-targeting technology, Antibody-Cell Conjugation (ACC), Acepodia believes it can develop powerful, accessible cell therapies for patients with cancer.
Acepodia has already advanced several cell therapy candidate programs into the clinical stage: The first is ACE1702, , a HER2-targeting NK cell therapy candidate. Following that are ACE1831 and ACE2016, gamma delta T cell therapies aimed at CD20-expressing hematological tumors and EGFR-expressing solid tumors, respectively. These drugs are undergoing Phase I clinical trials simultaneously in Taiwan and the United States. The company is also expanding the application of cell therapy drugs to the treatment of autoimmune diseases and is currently planning to apply for a Phase I clinical trial with the U.S. FDA.
2017 | Acepodia was founded in the United States and Taiwan. |
2018 | Acepodia completed USD 10 million in Series A fundraising |
2020 | Acepodia received US FDA clearance of IND for ACE1702’s Phase 1 clinical study. |
2020 | Acepodia and JW Therapeutics Enter into Option and License Agreement for Off-the-shelf NK Cell Therapies. |
2021 | Acepodia completed USD 47 million in Series B fundraising. |
2021 | Acepodia received TFDA approval of IND for ACE1702’s phase1 clinical study. |
2021 | Acepodia completed USD 109 million in Series C fundraising. |
2022 | Acepodia Presents Preclinical Data on its gamma delta T cell Therapy Candidate ACE1831 at 2022 AACR Meeting. |
2023 | Acepodia Announces First Patient Dosed in Phase 1 Clinical Trial of ACE1831, an Anti-CD20 Armed Allogeneic Gamma Delta T-cell Therapy in Development to Treat Patients with Non-Hodgkin’s Lymphoma |
2023 | Acepodia Secures $100 Million Series D Financing to Advance First-in-Class Cell Therapies with Antibody-Cell Conjugation (ACC) Platform |
2023 | Acepodia Announces Emerging Stock Listing on The Taipei Exchange |
2023 | Acepodia Announces Nobel Laureate Carolyn Bertozzi, Ph.D., as Chief Scientific Advisor |
2024 | Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy |
2024 | Acepodia Enters Strategic Clinical Collaboration with Pfizer to Accelerate Development of Antibody-Cell Conjugation-Based Cell Therapies in Autoimmune Diseases |